Spotlight On... Shire to take on hemophilia marketing with long-sought Baxalta buy; Walgreens eyes more specialty deals with drugmakers; Sanofi Pasteur's new commercial SVP to keep current agencies; and more...

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

> Walgreens ($WBA) it's looking at follow-up specialty pharmacy deals with drugmakers, now that it has sealed a pact with troubled Valeant Pharmaceuticals ($VRX) on a slate of its meds. Report

> Sanofi Pasteur tapped David Loew as its new SVP for global commercial operations; the French drugmaker said its agency relationships won't change, nor will its commercial strategy. Report

> Swedish Orphan Biovitrium said Elocta, a long-acting hemophilia A treatment it developed with Biogen ($BIIB), has been launched in Europe. Release

> Valneva said its Japanese encephalitis vaccine won approval in Taiwan through its partner there, Adimmune. Report

And Finally... A large new study, published in the BMJ, found no risk of birth defects from oral contraceptives. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.